Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heterocyclic modulators of lipid synthesis

A fatty acid synthase and cycloalkyl technology, which can be used in peptide/protein components, active ingredients of heterocyclic compounds, and medical preparations containing active ingredients, etc., and can solve the problem of not being approved.

Active Publication Date: 2019-08-27
3 V BIOSCI INC
View PDF33 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite available treatments for diabetes and cardiovascular disease, there are currently no drugs approved for the treatment of metabolic syndrome, NAFLD, or NASH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic modulators of lipid synthesis
  • Heterocyclic modulators of lipid synthesis
  • Heterocyclic modulators of lipid synthesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[5669] Example 1 - FASN Inhibition by Compounds of the Disclosure

[5670] Determination of FASN biochemical activity: FASN enzyme was isolated from SKBr3 cells. SKBr3 is a human breast cancer cell line with high expression levels of FASN. FASN is expected to comprise about 25% of the cytosolic protein in this cell line. SKBr3 cells were homogenized in a dounce homogenizer, followed by centrifugation at 4°C for 15 minutes to remove particulate matter. Supernatants were then analyzed for protein content, diluted to appropriate concentrations and used to measure FASN activity. The presence of FASN was confirmed by immunoblot analysis. A similar method for isolation of FASN from SKBr3 cells is described in Teresa, P. et al., (Clin. Cancer Res. 2009; 15(24), 7608-7615).

[5671] FASN activity of SKBr3 cell extracts was determined by measuring NADPH oxidation or the amount of thiol-containing coenzyme A (CoA) released during the fatty acid synthase reaction. The dye CPM (7-d...

Embodiment 2

[5672] Example 2 - Antiviral Activity

[5673] The antiviral activity of constructs (I-Z) was assessed using the HCV 1b replicon system:

[5674]

[5675] The replicon was constructed using the ET (luc-ubi-neo / ET) cell line, which is an HCV replicon with a stable luciferase (Luc) reporter and Three cell culture-adaptive mutant Huh7 human hepatoma cell lines (Pietschmann et al. (2002) J. Virol. 76:4008-4021). The HCV Replicon Antiviral Evaluation Assay investigated the effect of compounds at six half-log concentrations. Human interferon alpha-2b was included in each run as a positive control compound. Sub-confluent cultures of the ET line were plated out in 96-well plates dedicated to analysis of cell number (cytotoxicity) or antiviral activity and drugs were added to the appropriate wells the next day. Cells were processed 72 hours later when they were still near confluence. Determination of EC 50 (the replicon was inhibited by 50% and 90% respectively), IC 50 (conc...

Embodiment 3

[5678] Example 3 - FASN Inhibition Correlates with HCV Inhibition

[5679] The antiviral activity of 15 compounds of the disclosure was measured using the HCV replicon system (numbers correlate to compounds in Table 1). According to published methods (Lohmann et al., (1999) Science 285(5424): 110-113; Lohmann et al., (2001) J. Virol 75(3): 1437-1449 and Qi et al., (2009) Antiviral Res .81(2):166-173), Huh7 was used to establish the replicon cell line 1b (HCV 1b / Luc-Neo replicon (1b Con1 integrated firefly gene)) by G418 selection. Replicon assembly using synthetic gene fragments. The GT1b line has PV-EKT and has 3 adaptive mutations E1202G (NS3), T1280I (NS3), K1846T (NS4B) and the backbone is Con1. The medium is:

[5680] DMEM supplemented with 10% FBS, G418 (250 μg / ml), streptomycin (100 μg / ml) / penicillin (100 U / ml), L-glutamine (100×), NEAA (100×)

[5681] Culture medium was prepared as follows:

[5682] 500 ml DMEM medium (Gibco, catalog number 11960-077)

[5683] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

Description

[0001] related application [0002] This application claims priority and benefit from: U.S. Provisional Application No. 62 / 574,497, filed October 19, 2017; and U.S. Application No. 15 / 349,960, filed November 11, 2016, U.S. Application No. 15 / 349,960 is a continuation-in-part of U.S. Application Serial No. 14 / 874,961, filed October 5, 2015, which is a now-abandoned U.S. Application Serial No. 14 / 315,133, filed June 25, 2014 Continuation of U.S. Application No. 14 / 315,133 is a continuation of U.S. Application No. 13 / 415,660 filed March 8, 2012, now U.S. Patent No. 8,871,790, U.S. Application No. 13 / 415,660, now U.S. Patent No. 8,871,790 requires earlier filed U.S. Provisional Application No. 61 / 450,561, filed March 8, 2011, U.S. Provisional Application No. 61 / 508,611, filed July 16, 2011, and U.S. Provisional Application No. 61 / 508,611, filed January 11, 2012 61 / 585,642 and is a continuation-in-part of U.S. Application No. 15 / 201,824, filed July 5, 2016, which is a continuation-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/337A61K31/4155A61K31/4178A61K31/422A61K31/451A61K31/4525A61K31/454A61K31/4545
CPCA61K31/451A61K31/4525A61K31/454A61K31/4545A61K31/55A61K31/5377A61P35/00A61P31/12A61P31/20A61P31/16A61P3/00A61P3/10A61P1/16A61P29/00A61P3/06A61P17/06A61P19/02A61P1/00A61P11/06A61P37/06A61P5/50A61P17/00C07D401/14C07D405/14C07D413/14C07D401/10C07D405/12C07D471/04C07D487/04C07D487/10C07D491/052C07D211/38A61K31/7056A61K31/4418A61K31/453A61K45/06A61K31/4178A61K31/4155A61K38/00A61P1/02A61P1/04A61P11/00A61P11/04A61P17/02A61P19/08A61P25/00A61P31/14A61P37/02A61P43/00A61P9/00A61P9/04A61K2300/00A61K31/337A61K31/422C07D403/10C07D401/12C07D211/26C07D491/107C07D513/04
Inventor D·I·巴克利G·杜克A·S·瓦格曼M·埃文契克R·S·麦克道尔
Owner 3 V BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com